My scientific interest is in investigating the molecular mechanisms of cardiovascular disease. Our most recent work employed genomic methods to identify new diagnostic biomarkers of coronary artery disease, with applications for both clinical diagnostics and potential new therapeutic targets. My group is now heavily invested in next-generation sequencing (NGS), particularly RNAseq, as a strategy to simultaneously obtain precise RNA transcript levels, splicing, allele usage, and microRNA/non-coding RNAs in human diseases. We have applied this cutting-edge technology to blood samples from patients with coronary artery disease, heart failure with left ventricular assist devices, attention-deficit hyperactivity disorder, and infectious diseases, especially biofilms. There is every reason to believe that RNA profiling of blood offers an entirely new strategy toward the diagnosis, prognosis, and therapeutic monitoring of a variety of human disorders.